Somaiya Mayur Ian
Chief Financial Officer
Somaiya Mayur Ian has filed 2 SEC Form 4 filings (9 transaction rows) across 1 company, with disclosures dating back to 2026. 2 of those filings fall inside the rolling window. Most recent filing: Jan 22, 2026.
On the most recent filing, Somaiya Mayur Ian is listed as Chief Financial Officer at NewAmsterdam Pharma Co N.V. Inside the rolling window, Somaiya Mayur Ian reported no open-market purchases and 3 open-market sales totaling $3.4M in NAMS. The largest disclosed transaction in the window is a sale of 60,216 NAMS shares on Jan 20, 2026, worth $1.9M.
Companies traded
Other insiders at NAMS
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$3.4M
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Somaiya Mayur Ian made?
Somaiya Mayur Ian has filed 2 SEC Form 4 filings (9 transaction rows) across 1 company since 2026.
Which companies does Somaiya Mayur Ian trade?
Somaiya Mayur Ian has filed SEC Form 4 disclosures for 1 company, including NAMS.
When was Somaiya Mayur Ian's most recent SEC Form 4 filing?
Somaiya Mayur Ian's most recent SEC Form 4 filing on Tracefour is dated Jan 22, 2026.
What is Somaiya Mayur Ian's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Somaiya Mayur Ian is listed as Chief Financial Officer.
What is Somaiya Mayur Ian's total buy and sell value in the current window?
Inside the rolling retention window, Somaiya Mayur Ian bought $0 and sold $3.4M based on SEC Form 4 filings.
What was Somaiya Mayur Ian's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 60,216 NAMS shares on 2026-01-20, worth $1.9M, per SEC Form 4 filings.